Could a2 Milk, Bubs and CSL benefit from the Coronavirus?

Markets continue to prove volatile, as concerns over the economic impact of the Coronavirus grow.

While many stocks focused on healthcare and health products may ‘benefit’ from the Coronavirus; whether such benefits become reflected in the share prices of these companies – in the short or even medium-term, is another matter entirely.

Indeed, in an environment where investors may be seriously considering de-risking their portfolios – equities – even the best ones, often run in to trouble.

We’ve seen that clearly in the last week, as some of the world’s largest and most profitable companies have been sold-down by double-digits.

The ASX was savaged by investors today (though it crept up as the day wore on); and though US futures are currently pointing towards gains across the DOW, NASADQ and S&P500, last week was actually the worst for global stocks since the GFC.

Do you think this sell-off has been overdone, or is it just getting started? Trade indices long and short with an IG Trading Account today.

CSL share price in focus

‘Pandemics make the healthcare sector interesting,' says Graham Witcomb, from the Intelligent Investor.

Speaking of the Coronavirus (COVID-19) impact on ASX stocks more directly, Mr Witcomb recently said that:

‘CSL, one of the world's largest flu vaccine makers, may [...] benefit,’ from the Coronavirus.

Mr Witcomb goes on to say that ‘CSL is one of Australia's highest-quality companies and major mispricings are rare; the stock isn't far from fair value. We'd be interested below $200.’

Yet with CSL’s share bobbing around the $300 mark, it currently stands well below those mandated ‘interest’ levels.

A2 Milk and Bubs share prices prove volatile

Other ‘health’ related stocks such A2M and BUB have performed intriguingly in the last month or so.

A2 Milk for example, in its most recent set of interim results noted that it had actually seen an uptick in sales during the first weeks of H2. Here, the IMF company noted:

'Given the essential nature of our products for many Chinese families, demand is strong, particularly through online and reseller channels, with revenue for the first two months of 2H20 above expectations. However this is a dynamic situation and at this stage we are unable to quantify the impact, either positively or negatively, for the full year.’

A2 Milk has actually seen its share price rise in the last month, up 7.63% in that period. The stock however proved volatile today: trading in the red for most of the day before drifting higher as the session wore on.

A2’s small-cap counterpart – Bubs, has fared significantly less well in the last month. This comes even after Bubs reminded investors of infant formula’s ‘essential nature’, and noted that:

'To date Bubs Australia has seen no diminution of demand and minimal disruption to the business due to the Coronavirus outbreak.'

Citi analysts, speaking of A2’s Interim Results even said:

‘We see a2 returning to its roots of rewarding investors with consistent earnings upgrades and, while also factoring in upside risk to 2H20, we see the stock likely to react positively. The China outlook also bodes well for Bubs.'

Even so, the Bubs share price has declined ~10% in the last month.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.


Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.